- Progress on biosimilar pipeline paves way for five planned launches by 2020
- Sandoz now plans a total of 11 biosimilar filings by end 2017 (EU and US) and has already delivered on six
- Investments of more than USD 1 billion in state of-the-art biomanufacturing facilities, backed by industry-leading capabilities as part of Novartis, positions Sandoz to deliver biosimilars at unprecedented scale
Holzkirchen, June 20, 2016 – Sandoz, a Novartis Division and the global leader in biosimilars, plans to launch five biosimilars of major oncology and …